BPC-157 vs TB-500: Research Comparison Guide | Regena

BPC-157 is a 15-amino-acid synthetic fragment derived from a sequence first characterised in gastric-juice research literature. TB-500 is a synthetic 17-amino-acid fragment corresponding to the actin-binding region of thymosin β-4.

BPC-157 is most often discussed in the angiogenesis literature — VEGFR2 signalling, nitric-oxide pathway modulation and growth-factor expression in connective-tissue research models. TB-500 is studied for actin sequestration: its central KLKKTET motif binds G-actin and is associated with cell migration and remodelling in research literature.

The two compounds act on different layers of tissue-remodelling research models — BPC-157 on vascular and growth-factor signalling, TB-500 on the cytoskeletal actin pool. Researchers comparing the two typically note complementary rather than overlapping pathway coverage.

Both peptides ship lyophilised and are stored at 2–8°C before reconstitution. Bacteriostatic water is the standard reconstitution solvent; refrigerated in-use storage applies to both. TB-500's larger fragment size does not change standard handling practice.

Every Regena batch of BPC-157 and TB-500 ships with HPLC purity and mass-spec identity documentation, available on the lab reports page. Lot numbers on the vial label match the COA.

Selection depends on the pathway the protocol targets. Angiogenesis and growth-factor endpoints typically reference BPC-157; actin-dynamics and migration endpoints typically reference TB-500. Always cross-check current literature before designing an in-vitro study.